These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 9410329)
21. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Howard K; Barratt A; Mann GJ; Patel MI Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680 [TBL] [Abstract][Full Text] [Related]
22. Prostate cancer in Victoria in 1993: patterns of reported management. Frydenberg M; Giles GG; Mameghan H; Thursfield VJ; Millar J; Wheelahan JB; Bolton DM; Syme RR Med J Aust; 2000 Mar; 172(6):270-4. PubMed ID: 10860092 [TBL] [Abstract][Full Text] [Related]
23. [Characteristics of screening-detected prostate cancer on health checkup]. Uchida K; Akaza H Gan To Kagaku Ryoho; 1998 Aug; 25(10):1527-32. PubMed ID: 9725044 [TBL] [Abstract][Full Text] [Related]
24. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363 [TBL] [Abstract][Full Text] [Related]
25. [Chances and risks of prevention in elderly people for the three major cancers: breast-, prostate- and colorectal cancers]. Kolb GF Zentralbl Gynakol; 2006 Jun; 128(3):123-8. PubMed ID: 16758377 [TBL] [Abstract][Full Text] [Related]
26. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712 [TBL] [Abstract][Full Text] [Related]
28. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. Noguchi M; Stamey TA; Neal JE; Yemoto CE J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175 [TBL] [Abstract][Full Text] [Related]
29. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765 [TBL] [Abstract][Full Text] [Related]
30. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597 [TBL] [Abstract][Full Text] [Related]
31. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. Roobol MJ; Grenabo A; Schröder FH; Hugosson J J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218 [TBL] [Abstract][Full Text] [Related]
32. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232 [TBL] [Abstract][Full Text] [Related]
33. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082 [TBL] [Abstract][Full Text] [Related]
34. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Bunker CH; Patrick AL; Konety BR; Dhir R; Brufsky AM; Vivas CA; Becich MJ; Trump DL; Kuller LH Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):726-9. PubMed ID: 12163325 [TBL] [Abstract][Full Text] [Related]
35. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735 [TBL] [Abstract][Full Text] [Related]
36. Early outcomes of active surveillance for localized prostate cancer. Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912 [TBL] [Abstract][Full Text] [Related]
37. "Just Another Statistic". Machtay M; Glatstein E Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105 [TBL] [Abstract][Full Text] [Related]
38. Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume. Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Takeuchi H J Urol; 2000 Nov; 164(5):1587-90. PubMed ID: 11025710 [TBL] [Abstract][Full Text] [Related]
39. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126 [TBL] [Abstract][Full Text] [Related]
40. Diagnosis, management and screening of early localised prostate cancer. Selley S; Donovan J; Faulkner A; Coast J; Gillatt D Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]